search
Back to results

Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents (TeKnO T1D)

Primary Purpose

Type 1 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
TeKnO T1D: Parents
Sponsored by
Children's Hospital of Philadelphia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type 1 Diabetes focused on measuring pediatric, continuous glucose monitor, insulin pump, automated insulin delivery, hybrid closed loop systems, medical education, diabetes technology

Eligibility Criteria

8 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. child 8-12 years of age with a diagnosis of T1D ≥ 6 months
  2. currently using insulin pump( IP) and CGM ≥ 1 month [including Hybrid Closed Loop (HCL) systems]
  3. participation of primary diabetes caregiver
  4. English fluency
  5. mean A1c >7.5% over the past 6 months (Aim 3 only)

Exclusion Criteria:

  1. major illnesses other than T1D in the child
  2. significant cognitive limitations or major psychiatric disorders in the child or parent
  3. the use of medications other than insulin to control blood glucose levels.

Sites / Locations

  • Childrens Hospital of PhiladelphiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Active Comparator

Arm Label

Arm 1: Semi-structured Interviews

Arm 2: Designing an App Delivered Curriculum

Arm 3: TeKnO T1D: Parents Pilot Study

Arm Description

Arm 1 will be conducted from months 0-15 and will use interviews to better understand existing challenges in diabetes technology educational practices. It is not a clinical trial, but is a crucial part of what builds to the clinical trial.

Arm 2 will be conducted from months 10-33 and will use information learned in arm 1 to develop and beta test an educational curriculum. Arm 2 also is not a clinical trial, but is a crucial part of what builds to the clinical trial.

Arm 3 will be conducted from months 30-60 and involves a pilot and feasibility study of the newly developed educational curriculum. This is the clinical trial.

Outcomes

Primary Outcome Measures

Study Recruitment
Percentage of eligible patients who are approached and enroll in the study in Arm 3.
Intervention Satisfaction
Score on a survey developed to assess satisfaction with the Technology Knowledge Optimization Type 1 Diabetes: Parents curriculum in Arm 3. Scores range from 0-100 with higher scores reflecting greater satisfaction.
Perceived Intervention Utility
Score on a survey developed to assess the perceived utility of the Technology Knowledge Optimization Type 1 Diabetes: Parents curriculum during Arm 3. Scores range from 0-100 with higher scores reflecting greater perceived utility.
Intervention Completion
Percentage of enrolled participants who complete the TeKnO T1D: Parents Curriculum in Arm 3.
Intervention Retention
Percentage of enrolled participants who complete the entire intervention for Arm 3.

Secondary Outcome Measures

Hemoglobin A1c
Hemoglobin A1c will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Mean Sensor Glucose
CGM mean sensor glucose will be assessed prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Glucose Management Indicator
The Glucose Management Indicator will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Coefficient of Variation of the Mean
The Coefficient of Variation of the Mean will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. .
CGM Time in Range (70-180 mg/dL)
CGM Time in Range (70-180 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Time Below Range (<70 mg/dL)
CGM Time Below Range (<70 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Time Above Range (<180 mg/dL)
CGM Time Above Range (<180 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
CGM Wear Time
The percentage of CGM wear time will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Total Daily Insulin Dose
Total Daily Insulin Dose will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Total Daily Basal Insulin Dose
Total Daily Basal Insulin Dose will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Percent Basal Insulin Dose
The percentage of the total daily insulin derived from basal insulin (basal insulin/ total daily insulin dose) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Number of boluses per day
The number of boluses per day will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Carbohydrate intake logged on insulin pump
The number of grams of carbohydrate intake logged on insulin pump will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Episodes of Severe Hypoglycemia
The number of episodes of severe hypoglycemia will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Emergency Department Visits
The number of diabetes-related emergency department visits will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Hospital Admissions
The number of diabetes-related hospital admissions will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Episodes of Diabetic Ketoacidosis
The number of episodes of diabetic ketoacidosis will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Parent Diabetes-Specific Quality of Life
The Type 1 Diabetes and Life (T1DAL) is a validated survey assessing diabetes-specific quality of life. T1DAL will be will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater quality of life.
Parent Emotional Distress Related to T1D
Parents of Children (P-PAID) is a validated survey assessing emotional distress related to T1D. P-PAID will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 15 to 96 with higher scores reflecting greater emotional distress.
Parent Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ) is a validated survey assessing diabetes self-management. The DMQ will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater adherence to diabetes management.
Parent Perceived CGM Benefits and Burdens
CGM Benefits and Burdens scale is a validated survey exploring perceived benefits and burdens of CGM use. CGM Benefits and Burdens will be completed prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scoring of the CGM Benefits subscale ranges from 1 to 40 with higher scores reflecting greater perceived benefits. Scoring of the CGM Burdens subscale ranges from 1 to 40 with higher scores reflecting less perceived burden.
Parent Diabetes Technology Knowledge
A survey assessing diabetes technology knowledge will be developed. This survey will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater knowledge.
Child Diabetes-Specific Quality of Life
The Type 1 Diabetes and Life (T1DAL) is a validated survey assessing diabetes-specific quality of life. T1DAL will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater quality of life.
Child Emotional Distress Related to T1D
Problem Areas in Diabetes- Child Version (PAID-C) is a validated survey assessing emotional distress related to T1D. PAID-C will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion). Scores range from 11 to 84 with higher scores reflecting greater emotional distress.
Child Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ) is a validated survey assessing diabetes self-management. The DMQ will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater adherence to diabetes management.
Child Perceived CGM Benefits and Burdens
CGM Benefits and Burdens scale is a validated survey exploring perceived benefits and burdens of CGM use. CGM Benefits and Burdens will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scoring of the CGM Benefits subscale ranges from 1 to 40 with higher scores reflecting greater perceived benefits. Scoring of the CGM Burdens subscale ranges from 1 to 40 with higher scores reflecting less perceived burden.

Full Information

First Posted
December 18, 2021
Last Updated
March 13, 2023
Sponsor
Children's Hospital of Philadelphia
search

1. Study Identification

Unique Protocol Identification Number
NCT05300022
Brief Title
Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents
Acronym
TeKnO T1D
Official Title
Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 10, 2022 (Actual)
Primary Completion Date
July 2027 (Anticipated)
Study Completion Date
July 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Philadelphia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to identify the unmet psychoeducational needs of parents of children 8-12 years of age using insulin pump and CGM for pediatric T1D management and to leverage that information to develop an innovative app-based psychoeducational intervention to optimize use of these technologies and improve T1D outcomes.
Detailed Description
Despite increased use of insulin pumps and continuous glucose monitors (CGM) for pediatric type 1 diabetes (T1D) management and research studies showing benefits from the use of these devices, real-world glycemic control among youth with T1D has worsened in recent years. Although greater youth and parental diabetes knowledge is associated with better glycemic control, education alone is not sufficient to bring about the behavioral changes needed to improve outcomes in T1D. Psychoeducation recognizes the need to blend educational and behavioral approaches, including problem-solving and goal-setting, to support parents in developing optimal T1D management approaches. There are currently a lack of effective standardized tools to support patients and families in developing the knowledge and behavioral strategies needed to optimize the use of diabetes technologies. The development of innovative family-centered psychoeducational tools addressing both behavior and knowledge will help to realize the full potential of diabetes technologies to improve glycemic control and quality of life while ultimately preventing or delaying the development of both acute and long-term complications of T1D. Interviews with parent-child dyads and diabetes clinicians will be used to identify the unmet parental psychoeducational needs regarding insulin pumps and CGM. These results will inform the use of instructional design to adapt an existing app-delivered diabetes technology curriculum to meet the specific needs of parents of children with T1D. Finally, the investigators will assess the feasibility and acceptability of this novel family-facing psychoeducational app-delivered intervention in a non-randomized pilot study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
pediatric, continuous glucose monitor, insulin pump, automated insulin delivery, hybrid closed loop systems, medical education, diabetes technology

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1: Semi-structured Interviews
Arm Type
No Intervention
Arm Description
Arm 1 will be conducted from months 0-15 and will use interviews to better understand existing challenges in diabetes technology educational practices. It is not a clinical trial, but is a crucial part of what builds to the clinical trial.
Arm Title
Arm 2: Designing an App Delivered Curriculum
Arm Type
Experimental
Arm Description
Arm 2 will be conducted from months 10-33 and will use information learned in arm 1 to develop and beta test an educational curriculum. Arm 2 also is not a clinical trial, but is a crucial part of what builds to the clinical trial.
Arm Title
Arm 3: TeKnO T1D: Parents Pilot Study
Arm Type
Active Comparator
Arm Description
Arm 3 will be conducted from months 30-60 and involves a pilot and feasibility study of the newly developed educational curriculum. This is the clinical trial.
Intervention Type
Other
Intervention Name(s)
TeKnO T1D: Parents
Intervention Description
app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
Primary Outcome Measure Information:
Title
Study Recruitment
Description
Percentage of eligible patients who are approached and enroll in the study in Arm 3.
Time Frame
Arm 3: Months 30-60
Title
Intervention Satisfaction
Description
Score on a survey developed to assess satisfaction with the Technology Knowledge Optimization Type 1 Diabetes: Parents curriculum in Arm 3. Scores range from 0-100 with higher scores reflecting greater satisfaction.
Time Frame
Arm 3: Months 30-60
Title
Perceived Intervention Utility
Description
Score on a survey developed to assess the perceived utility of the Technology Knowledge Optimization Type 1 Diabetes: Parents curriculum during Arm 3. Scores range from 0-100 with higher scores reflecting greater perceived utility.
Time Frame
Arm 3: Months 30-60
Title
Intervention Completion
Description
Percentage of enrolled participants who complete the TeKnO T1D: Parents Curriculum in Arm 3.
Time Frame
Arm 3: Months 30-60
Title
Intervention Retention
Description
Percentage of enrolled participants who complete the entire intervention for Arm 3.
Time Frame
Arm 3: Months 30-60
Secondary Outcome Measure Information:
Title
Hemoglobin A1c
Description
Hemoglobin A1c will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
CGM Mean Sensor Glucose
Description
CGM mean sensor glucose will be assessed prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
months 0-60
Title
CGM Glucose Management Indicator
Description
The Glucose Management Indicator will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
CGM Coefficient of Variation of the Mean
Description
The Coefficient of Variation of the Mean will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. .
Time Frame
Arm 3: Months 30-60
Title
CGM Time in Range (70-180 mg/dL)
Description
CGM Time in Range (70-180 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
CGM Time Below Range (<70 mg/dL)
Description
CGM Time Below Range (<70 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
CGM Time Above Range (<180 mg/dL)
Description
CGM Time Above Range (<180 mg/dL) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
CGM Wear Time
Description
The percentage of CGM wear time will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Total Daily Insulin Dose
Description
Total Daily Insulin Dose will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Total Daily Basal Insulin Dose
Description
Total Daily Basal Insulin Dose will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Percent Basal Insulin Dose
Description
The percentage of the total daily insulin derived from basal insulin (basal insulin/ total daily insulin dose) will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Number of boluses per day
Description
The number of boluses per day will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Carbohydrate intake logged on insulin pump
Description
The number of grams of carbohydrate intake logged on insulin pump will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Episodes of Severe Hypoglycemia
Description
The number of episodes of severe hypoglycemia will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Emergency Department Visits
Description
The number of diabetes-related emergency department visits will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Hospital Admissions
Description
The number of diabetes-related hospital admissions will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Episodes of Diabetic Ketoacidosis
Description
The number of episodes of diabetic ketoacidosis will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Parent Diabetes-Specific Quality of Life
Description
The Type 1 Diabetes and Life (T1DAL) is a validated survey assessing diabetes-specific quality of life. T1DAL will be will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater quality of life.
Time Frame
Arm 3: Months 30-60
Title
Parent Emotional Distress Related to T1D
Description
Parents of Children (P-PAID) is a validated survey assessing emotional distress related to T1D. P-PAID will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 15 to 96 with higher scores reflecting greater emotional distress.
Time Frame
Arm 3: Months 30-60
Title
Parent Diabetes Self-Management
Description
The Diabetes Management Questionnaire (DMQ) is a validated survey assessing diabetes self-management. The DMQ will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater adherence to diabetes management.
Time Frame
Arm 3: Months 30-60
Title
Parent Perceived CGM Benefits and Burdens
Description
CGM Benefits and Burdens scale is a validated survey exploring perceived benefits and burdens of CGM use. CGM Benefits and Burdens will be completed prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scoring of the CGM Benefits subscale ranges from 1 to 40 with higher scores reflecting greater perceived benefits. Scoring of the CGM Burdens subscale ranges from 1 to 40 with higher scores reflecting less perceived burden.
Time Frame
months 0-60
Title
Parent Diabetes Technology Knowledge
Description
A survey assessing diabetes technology knowledge will be developed. This survey will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater knowledge.
Time Frame
Arm 3: Months 30-60
Title
Child Diabetes-Specific Quality of Life
Description
The Type 1 Diabetes and Life (T1DAL) is a validated survey assessing diabetes-specific quality of life. T1DAL will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater quality of life.
Time Frame
Arm 3: Months 30-60
Title
Child Emotional Distress Related to T1D
Description
Problem Areas in Diabetes- Child Version (PAID-C) is a validated survey assessing emotional distress related to T1D. PAID-C will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion). Scores range from 11 to 84 with higher scores reflecting greater emotional distress.
Time Frame
Arm 3: Months 30-60
Title
Child Diabetes Self-Management
Description
The Diabetes Management Questionnaire (DMQ) is a validated survey assessing diabetes self-management. The DMQ will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scores range from 0 to 100 with higher scores reflecting greater adherence to diabetes management.
Time Frame
Arm 3: Months 30-60
Title
Child Perceived CGM Benefits and Burdens
Description
CGM Benefits and Burdens scale is a validated survey exploring perceived benefits and burdens of CGM use. CGM Benefits and Burdens will be completed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion. Scoring of the CGM Benefits subscale ranges from 1 to 40 with higher scores reflecting greater perceived benefits. Scoring of the CGM Burdens subscale ranges from 1 to 40 with higher scores reflecting less perceived burden.
Time Frame
Arm 3: Months 30-60
Other Pre-specified Outcome Measures:
Title
Qualitative analysis of semi-structured interviews
Description
Semantic content analysis will identify widely captured themes pertaining to diabetes technology education so as to prioritize content to include in curriculum development.
Time Frame
Arm 1: Months 0-15
Title
TeKnO T1D: Parents Curriculum difficulty
Description
Using classical test theory as our framework, the investigators will conduct an item analysis to assess the quality of the items and the overall test, including item difficulty.
Time Frame
Arm 2: Months 10-33
Title
TeKnO T1D: Parents Curriculum discrimination
Description
Using classical test theory as our framework, the investigators will conduct an item analysis to assess the quality of the items and the overall test, including item discrimination.
Time Frame
Arm 2: Months 10-33
Title
Child Weight Z-score
Description
Weight Z-score for age will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Child Height Z-score
Description
Height Z-score for age will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60
Title
Child BMI Z-score
Description
BMI Z-score for age will be assessed in Arm 3 prior to the curriculum start, upon completion of the TeKnO T1D: Parents curriculum, and 12 weeks after the curriculum completion.
Time Frame
Arm 3: Months 30-60

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: child 8-12 years of age with a diagnosis of T1D ≥ 6 months currently using insulin pump( IP) and CGM ≥ 1 month [including Hybrid Closed Loop (HCL) systems] participation of primary diabetes caregiver English fluency mean A1c >7.5% over the past 6 months (Aim 3 only) Exclusion Criteria: major illnesses other than T1D in the child significant cognitive limitations or major psychiatric disorders in the child or parent the use of medications other than insulin to control blood glucose levels.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reshma Suresh
Phone
(215)-590-3202
Email
sureshr@chop.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brynn E Marks, MD, MSHPEd
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Childrens Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19146
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Beth Schwartzman
Phone
215-590-3174
Email
schwartzmann@chop.edu
First Name & Middle Initial & Last Name & Degree
Brynn Marks, MD, MSHPEd
Email
marksb@chop.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents

We'll reach out to this number within 24 hrs